You are here: Industry Insights > teva

News List

Cash-strapped Teva closes in on women's health sale No. 2: report fiercepharma
September 18, 2017
Teva earlier this week inked a pact to sell off one of its women’s health products—and now it’s closing in on a deal to divest that business’s assets outside the U.S.
Teva scores expanded indication for Austedo in tardive dyskinesia pharmafile
September 01, 2017
Following the FDA’s approval of Teva’s Austedo (deutetrabenazine) in the treatment of chorea associated with Huntington’s disease in April this yea
Teva kept silence for weeks on upcoming generics blow fiercepharma
August 14, 2017
Teva last week walked back 2017 sales guidance by more than $1 billion for the second time this year.
Teva Announces FDA Approval of QVAR RediHaler americanpharmaceuticalreview
August 11, 2017
Teva Pharmaceutical announced the U.S. Food and Drug Administration (FDA) has approved QVAR RediHaler inhalation aerosol, a breath-actuated inhaler for the maintenance treatment of asthma as a prophylactic therapy in patients 4 years of age and older.
Teva puts Medis—and maybe more—on the block to help ease its debt woes fiercepharma
August 10, 2017
Teva has already said it's looking for buyers for its women's health and European oncology and pain businesses.
How much will Teva need to pay to land the CEO it's promised investors? fiercepharma
August 08, 2017
Now that the struggling drugmaker has recut its guidance, slashed its dividend and cautioned investors that it may breach its debt covenants, “they have to pay more than market,” analysts and investors told The Wall Street Journal.
Teva gets FDA approval for easier-to-use inhaler pharmatimes
August 08, 2017
The FDA has approved Teva’s QVAR RediHaler (beclomethasone dipropionate HFA) inhalation aerosol, a breath-actuated inhaler for the maintenance treatment of asthma.
Celltrion, Teva Announce FDA Acceptance of BLA for Proposed Biosimilar to Herceptin americanpharmaceuticalreview
August 02, 2017
Celltrion and Teva Pharmaceutical Industries announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for CT-P6
Discount helps NICE flip-flop on Teva's severe asthma contender, Cinqair fiercepharma
July 21, 2017
There’s still no word on whether Teva has landed AstraZeneca CEO Pascal Soriot or if he is staying put, as later reports said. But in the meantime, the drugmaker got some good news Thursday on the respiratory front.
Teva, Xenon Announce Phase II Study of Topical TV-45070 Did Not Meet Primary Endpoint americanpharmaceuticalreview
June 28, 2017
Teva Pharmaceutical and Xenon Pharmaceuticals announce top-line results in a Phase II study of topical TV-45070 in patients with post-herpetic neuralgia (PHN) did not meet the primary endpoint of a statistically significant change in pain from baseline to

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page